Check for updates

OPEN ACCESS

EDITED BY Yanzhou Yang, Ningxia Medical University, China

REVIEWED BY Fenglei Chen, Yangzhou University, China

*CORRESPONDENCE Miyuki Harada Maradam-tky@umin.ac.jp

SPECIALTY SECTION This article was submitted to Reproduction, a section of the journal Frontiers in Endocrinology

RECEIVED 15 December 2022 ACCEPTED 02 February 2023 PUBLISHED 15 February 2023

CITATION

Koike H, Harada M, Kusamoto A, Xu Z, Tanaka T, Sakaguchi N, Kunitomi C, Azhary JMK, Takahashi N, Urata Y and Osuga Y (2023) Roles of endoplasmic reticulum stress in the pathophysiology of polycystic ovary syndrome. *Front. Endocrinol.* 14:1124405. doi: 10.3389/fendo.2023.1124405

COPYRIGHT

© 2023 Koike, Harada, Kusamoto, Xu, Tanaka, Sakaguchi, Kunitomi, Azhary, Takahashi, Urata and Osuga. This is an openaccess article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or

reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Roles of endoplasmic reticulum stress in the pathophysiology of polycystic ovary syndrome

Hiroshi Koike¹, Miyuki Harada^{1*}, Akari Kusamoto¹, Zixin Xu¹, Tsurugi Tanaka¹, Nanoka Sakaguchi¹, Chisato Kunitomi¹, Jerilee M. K. Azhary^{1,2}, Nozomi Takahashi¹, Yoko Urata¹ and Yutaka Osuga¹

¹Department of Obstetrics and Gynecology, Faculty of Medicine, The University of Tokyo, Tokyo, Japan, ²Department of Obstetrics and Gynaecology, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia

Polycystic ovary syndrome (PCOS) is the most common endocrine disorder among reproductive-age women, affecting up to 15% of women in this group, and the most common cause of anovulatory infertility. Although its etiology remains unclear, recent research has revealed the critical role of endoplasmic reticulum (ER) stress in the pathophysiology of PCOS. ER stress is defined as a condition in which unfolded or misfolded proteins accumulate in the ER because of an imbalance in the demand for protein folding and the protein-folding capacity of the ER. ER stress results in the activation of several signal transduction cascades, collectively termed the unfolded protein response (UPR), which regulates various cellular activities. In principle, the UPR restores homeostasis and keeps the cell alive. However, if the ER stress cannot be resolved, it induces programmed cell death. ER stress has recently been recognized to play diverse roles in both physiological and pathological conditions of the ovary. In this review, we summarize current knowledge of the roles of ER stress in the pathogenesis of PCOS. ER stress pathways are activated in the ovaries of both a mouse model of PCOS and in humans, and local hyperandrogenism in the follicular microenvironment associated with PCOS is responsible for activating these. The activation of ER stress contributes to the pathophysiology of PCOS through multiple effects in granulosa cells. Finally, we discuss the potential for ER stress to serve as a novel therapeutic target for PCOS.

KEYWORDS

endoplasmic reticulum stress (ER stress), pathophysiology, polycystic ovary syndrome (PCOS), unfolded protein response (UPR), follicular microenvironment, ovary

1 Introduction

Polycystic ovary syndrome (PCOS) is the most common endocrine/metabolic disorder in women of reproductive age and presents with various symptoms, including oligomenorrhea, infertility, cutaneous manifestations, and metabolic disorders (1). Although its etiology remains unclear, recent research has revealed that intraovarian local factors play crucial roles

in the pathophysiology of PCOS (2). The ovary is a dynamic organ: it is a site for follicular growth, oocyte maturation, ovulation, and corpus luteum formation in women of reproductive age. The ovarian follicular microenvironment, which includes gonadotropins and intraovarian local factors, is a key regulator of this dynamic process. Endoplasmic reticulum (ER) stress has recently been recognized to be a local factor in the follicular microenvironment (3). ER stress is caused by the accumulation of unfolded or misfolded proteins in the ER, and induces the activation of several signaling cascades that mediate its resolution and restore cellular homeostasis but also induce programmed cell death if this resolution is not possible. ER stress plays crucial roles in various pathological conditions and recent studies have shown that ER stress is involved in the pathogenesis of PCOS (1, 3, 4). To improve the healthcare of women with PCOS, it is important to better understand the pathophysiology of PCOS. In this review, we summarize current knowledge of the roles of ER stress in the pathogenesis of PCOS.

2 Polycystic ovary syndrome

PCOS is the most common endocrine or metabolic disorder in reproductive-age women and presents with heterogeneous and complex symptoms (1, 5, 6). For its diagnosis, the 2003 Rotterdam criteria are widely used. These require at least two out of the following three characteristics: clinical and/or biochemical hyperandrogenism (HA), ovulatory dysfunction, and polycystic ovarian morphology (7). The metabolic dysfunction related to insulin resistance (IR) is also a feature of PCOS, although IR is not included in the listed criteria (8).

HA and IR are the most important contributors to the pathophysiology of PCOS (1). HA disturbs the function of hypothalamic-pituitary-ovarian (HPO) axis: it causes abnormal gonadotropin-releasing hormone (GnRH) secretory pulses, resulting in high levels of luteinizing hormone, which further increases androgen secretion by ovarian theca cells (TCs) (9). Abnormal secretion of both gonadotropins and androgens disturbs ovarian function, including follicular development, steroid hormone secretion, oocyte maturation, and ovulation. In addition, high levels of anti-Müllerian hormone (AMH), which is secreted by the pre-/ small antral follicles that accumulate in the ovaries of women with PCOS, further worsens ovarian dysfunction by disturbing follicular development and GnRH pulsation (10, 11). IR and the compensatory hyperinsulinemia that are associated with visceral adiposity and adipocyte dysfunction further aggravate the HA and ovarian dysfunction (10).

Although the familial nature of PCOS has been recognized for decades, it is estimated that the genes responsible for the pathogenesis of PCOS account only for 10% of its heritability (12). Instead, it is now considered that PCOS is a multifactorial disorder that is influenced by environmental factors, such as the prenatal intrauterine environment of mothers, the follicular microenvironment of the ovary, and lifestyle following birth (1, 5, 13). Prenatal exposure to high concentrations of androgens, AMH, or insulin in the uterus of mothers with PCOS may contribute to the pathogenesis of PCOS. ER stress, the proinflammatory status, and oxidative stress in the follicular microenvironment are likely to be responsible for the ovarian features of PCOS, as discussed in the following sections in detail. In

addition, an unfavorable lifestyle predisposes toward the development of the metabolic features of PCOS.

3 Endoplasmic reticulum stress

The ER is a eukaryotic organelle that is principally involved in the synthesis, folding, maturation, and transportation of proteins, as well as in calcium homeostasis, lipid metabolism, and steroid synthesis. Cellular homeostasis is maintained by the competence of the ER to participate in these processes. However, under certain situations, such as cell proliferation and differentiation, hypoxia, or metabolic abnormalities, an imbalance between the functional capacity of the ER and the load causes cells to enter the state referred to as ER stress (14-17). ER stress causes the activation of a cellular adaptive mechanism, termed the unfolded protein response (UPR), to restore cellular homeostasis (Figure 1). However, severe or longlasting stress causes a switch from the adaptive UPR to the maladaptive UPR, ultimately leading toward apoptosis. Because of its essential roles in diverse cellular activities, ER stress and the UPR have been implicated in various pathological conditions, such as diabetes, neurodegenerative diseases, inflammatory diseases, and various types of malignancy (18-23). Furthermore, recent studies have shown that ER stress is closely associated with benign gynecological diseases, such as PCOS (1, 3, 4).

4 Pathophysiological role of ER stress in PCOS

Ovarian follicles consist of an oocyte, granulosa cells (GCs), and TCs. Follicular development is a well-coordinated process that includes oocyte maturation and the proliferation and differentiation of somatic cells, which are regulated by gonadotropins and intraovarian local factors that affect the follicular microenvironment (24, 25). Recently, it has been revealed that ER stress in the follicular microenvironment, followed by activation of the UPR, plays an important role in ovarian physiology and pathology (3, 22, 26). HA, IR, inflammation, and oxidative stress are all associated with PCOS and closely connected with ER stress (1, 23). We demonstrated for the first time that ER stress and the UPR are activated in GCs from both patients with PCOS and mice with androgen-induced PCOS (4). We also demonstrated that a high androgen concentration induces ER stress in cultured human GCs (27). It is conceivable that ER stress and several local factors form a vicious circle within the follicular microenvironment of patients with PCOS and contribute to the pathophysiology (1).

4.1 Apoptosis of GC

Bidirectional communication between GCs and oocytes, as well as between somatic cells, regulates follicular development and oocyte maturation (28–32). These interactions are mediated *via* cell-to-cell gap junctions and in a paracrine or juxtacrine manner (33–36). Disruption of intrafollicular crosstalk disturbs normal follicular




FIGURE 1

ER stress and the UPR pathway. Under ER stress, three sensor proteins located in the ER membrane are activated. Double-stranded RNA-activated protein kinase (PKR)-like ER kinase (PERK) and inositol requiring enzyme 1 (IRE1) are maintained in an inactive state by interaction with the ER chaperone glucose-regulated protein 78 (GRP78), and are activated by dimerization and self-phosphorylation when GRP78 binds to unfolded or misfolded proteins in the ER and is released from PERK and IRE1. PERK phosphorylates eukaryotic initiation factor 2α (eIF2 α) that causes translational arrest of most proteins to reduce overload of protein folding in the ER while facilitates translation of activating transcription factor 4 (ATF4). ATF4 induces the transcription of its target genes encoding factors involved in the ER chaperones, amino acid biosynthesis, oxidative stress response and apoptosis. CHOP induced by ATF4 activates apoptotic cascade through the induction of DR5 or Bcl-2-associated X protein (Bax)/Bcl-2 homologous antagonist/killer (Bak). IRE1 is activated by dimerization and self-phosphorylation causing X-box-binding protein 1 (XBP1) mRNA splicing *va* its endoribonuclease activity. Spliced XBP1 (XBP1s) protein induces transcription of UPR target genes involved in the ER chaperones, ER-associated degradation and cell homeostasis. IRE1 also cleaves ER-associated factor receptor-associated factor 2 (TRAF2), and activates apoptotic cascade through c-Jun N-terminal kinase (JNK) or caspase-12/4 signaling. Activating transcription factor 6 (ATF6) is activated by sequential cleavage in Golgi apparatus, releasing its active fragment, ATF6p50, which induces transcription of UPR target genes involved in the ER chaperones, ER-associated degradation of UPR target genes involved in the ER chaperones, ER-associated degradation and cell homeostasis.

development and results in follicular atresia. On the basis of these findings, it is thought that inappropriate apoptosis of GCs disturbs follicular development. Indeed, apoptotic GCs are more numerous in ovaries from patients and animal models with PCOS (37, 38). Androgens induce the apoptosis of cultured GCs by activating intrinsic apoptotic signaling or reducing the synthesis of follicular growth factors (39–41).

ER stress induces the expression of the proapoptotic factors C/ EBP homologous protein (CHOP) and death receptor 5 (DR5), which is high in the GCs of patients with PCOS (27). Treatment of cultured human GCs with testosterone activates several UPR pathways and DR5 and increases the apoptosis of these cells. These effects are attenuated by treatment with an ER stress inhibitor tauroursodeoxycholic acid (TUDCA). Treatment with TUDCA also attenuates the intrinsic apoptotic pathway, which is activated in the GCs of patients with PCOS (42). Furthermore, the administration of TUDCA to mice with PCOS reduces the apoptosis of GCs in antral follicles, and this is associated with a concomitant decrease in the expression of CHOP and DR5, which implies that ER stress activated by HA in PCOS promotes the apoptosis of GCs via CHOP followed by caspase cascade and follicular growth arrest (27). Similarly, treatment with curcumin, a polyphenol extracted from turmeric rhizomes, or traditional Chinese medicines abrogates androgeninduced ER stress and the apoptosis of GCs, both in vivo and in vitro (43-46). In addition, the high levels of oxidative stress that is founded in patients with PCOS cause the activation of the UPR in both the ER and mitochondria, resulting in the apoptosis of GCs (47).

4.2 Insulin resistance

IR and the resulting compensatory hyperinsulinemia are key components of PCOS pathophysiology, along with HA. IR is associated with significant alterations in ovarian function (48-51). Furthermore, hyperinsulinemia facilitates androgen secretion from the ovary and the adrenal gland and inhibits the hepatic synthesis of sex hormone-binding globulin, thereby increasing both total and free circulating androgen concentrations (52-54). In addition, HA induces visceral adiposity and adipocyte dysfunction, which cause IR. Therefore, IR and HA form a vicious circle. It has been proposed that ER stress underlies the development of IR by inhibiting insulin signaling in adipose tissue, skeletal muscle, and the liver (55-58). Pancreatic β-cells contain a large amount of ER, reflecting their insulin secretory function, and overwhelming demand for insulin secretion inevitably causes ER stress and β -cell dysfunction. Because of these findings, we will focus on the relationships among ER stress, IR, and HA in the pathophysiology of PCOS.

Both ER stress and the levels of proapoptotic factors are high in the pancreatic islets of mice with PCOS (59). Testosterone induces both of these abnormalities and the apoptosis of cultured islet cells, while the ER stress inhibitors TUDCA and 4-phenylbutylic acid (4-PBA), and the androgen receptor antagonist flutamide, ameliorate testosterone-induced ER stress and apoptosis in these cells (60). Moreover, the administration of flutamide to mice with PCOS ameliorates their hyperinsulinemia and the ER stress in their islet cells. It has been suggested that HA induces $\beta\text{-cell}$ dysfunction via the activation of ER stress in PCOS. Furthermore, several studies have shown that ER stress distant from the pancreas may also be involved in the pathogenesis of PCOS. The phosphatidylinositol-3 kinase (PI3K)/Akt pathway, which is a major insulin signaling pathway and decreased in PCOS patients, and the UPR in GCs are involved in the dysfunction of these cells (44). It is also thought that kisspeptin, a peptide that regulates the HPO axis, is involved in IR and ER stress in the hypothalamus of individuals with PCOS (61). The administration of curcumin; traditional Chinese medicines; or adrenomedullin, an endogenous vasodilator peptide, ameliorates IR, which is accompanied by a concomitant decrease in ER stress in the ovaries of animals with PCOS (44, 45, 62, 63). Accordingly, it is conceivable that ER stress activated by HA in PCOS, both in islet and nonpancreatic cells, contributes to the induction of IR, and IR in turn activates ER stress in these cells, resulting in dysfunction.

4.3 Ovarian fibrosis

The ovaries of patients with PCOS are characterized by thickening owing to greater collagen deposition and fibrosis (64). Transforming growth factor (TGF)- β is the key factor that drives fibrosis in various tissues (65, 66), and it has been reported that the serum concentration and ovarian expression of TGF- β 1 are higher in patients with PCOS (67, 68). Both TGF- β 1 and connective tissue growth factor (CTGF) in GCs have essential roles in extracellular matrix remodeling in the ovary (69–71), and it has also been shown that HA induces ovarian fibrosis *via* the TGF- β signaling pathway in a rat model (72, 73).

ER stress and TGF-B1 signaling in GCs are activated, and interstitial fibrosis is marked, in the ovaries of both patients and mice with PCOS (4). Furthermore, ER stress stimulates the expression of TGF-B1 and CTGF in cultured human GCs, and treatment with TUDCA has been shown to reduce ovarian fibrosis in mice with PCOS, which is accompanied by reductions in ER stress and TGF- β 1 expression. The concentrations of TGF- β 1 and CTGF are also high in the ovaries of rats with PCOS, but the administration of adrenomedullin reduces their ER stress and the ovarian concentrations of profibrotic factors (63). These findings suggest that ER stress contributes to ovarian fibrosis via the TGF- β 1 signaling pathway in the pathology of PCOS. Taken together with the findings that ER stress causes the activation of TGF- β signaling and fibrosis in various organs (74-76), it is conceivable that ER stress activated by HA in the ovaries of women with PCOS is implicated in the etiology of the interstitial fibrosis that characterizes the ovaries of women with PCOS.

4.4 Abnormal ovarian steroid hormone metabolism

In patients with PCOS, it has been shown that steroidogenic gene expression is altered in GCs (77), and that the concentrations of

estrogen and progesterone are low in both serum and follicular fluid (78-81). In addition to HA, ER stress affects both estrogen and progesterone production by GCs (82, 83). The concentrations of both hormones are lower in the culture medium of GCs derived from patients with PCOS than in that from control patients, and these concentrations are increased by TUDCA treatment, in association with a reduction in ER stress (42). The expression of the ovarian steroidogenic genes Cyp19a1 and Cyp11a1 is high in the ovaries of rats with PCOS (43). In addition, the expression of aryl hydrocarbon receptor (AHR) and Cyp1b1, which is a downstream target of AHR and metabolizes estrogen, is high in the GCs of patients and mice with PCOS (84). AHR is a well-established receptor for endocrinedisrupting chemicals (EDCs), which accumulate in the ovaries of women with PCOS, but it also plays diverse roles in metabolic, developmental, and pathologic processes (85-87). In the ovary, it has been demonstrated that the AHR signaling pathway is involved in follicular development and estradiol biosynthesis (88). ER stress increases the expression of AHR and Cyp1b1 in cultured human GCs, and the administration of an AHR inhibitor ameliorates the abnormal reproductive phenotype in mice with PCOS, including their estrous cyclicity and atretic follicle counts (85). These findings suggest that ER stress in the follicular microenvironment contributes to the disruption of steroid hormone metabolism as part of the pathophysiology of PCOS.

4.5 Cumulus oocyte complex expansion

Ovulatory dysfunction is one of the key phenotypes of PCOS. Ovulation is a complex process, during which the maturation of the oocyte and its release from an ovarian follicle occur in synchrony with dynamic tissue remodeling, including the expansion of cumulus oocyte complex (COC) (89–91).

The Notch pathway, which regulates cell fate via cell-to-cell juxtacrine interaction, is involved in various physiological and pathological processes, such as organogenesis and carcinogenesis (92-95). Notch signaling in the follicular microenvironment also regulates ovarian development, including follicular assembly and growth, steroidogenesis, and angiogenesis (34, 96, 97). Notch signaling is activated in the GCs of patients and mice with PCOS (98). The UPR activates Notch signaling followed by the induction of some ovulation-related genes in cultured human GCs. ER stress increases the expansion of cultured murine COCs through Notch signaling. Moreover, cumulus oocyte complex (COC) expansion is upregulated in mice with PCOS, which is attenuated by administration of a Notch signaling inhibitor. It has also been reported that ER stress and androgens induce the expansion of cultured murine COCs, and that this is reduced by treatment with TUDCA or metformin (99). These findings indicate that ER stress and the resulting activation of Notch signaling interferes with ovulation in PCOS.

4.6 Accumulation of advanced glycation end-products in the ovary

Advanced glycation end-products (AGEs) are endogenously produced through the Maillard reaction between sugars and the

free amino groups of proteins or other substrates (100), and are exogenously obtained in the diet and through smoking (101, 102). AGEs are proinflammatory factors and are involved in several diseases, including diabetes, metabolic syndrome, and cardiovascular disease. Patients with PCOS have high concentrations of Advanced glycation end-products (AGEs) in their serum and ovaries (103-105). AGEs bind to cell membrane receptors for AGEs (RAGE) and activate several proinflammatory signaling pathways, causing follicular growth arrest and ovulatory dysfunction (104, 105). ER stress induced by androgens is associated with increases in the expression of AGEs and RAGE in cultured human GCs (106). The administration of TUDCA to mice with PCOS reduces the accumulation of AGEs and the expression of RAGE and restores estrous cyclicity and follicular development. Thus, the HA associated with PCOS causes the accumulation of AGEs in the ovary by activating ER stress, resulting in follicular growth arrest.

5 Summary and future perspectives

ER stress is activated in the follicular microenvironment by HA and IR, two key components of the heterogenous etiology of PCOS. ER stress and the resulting activation of the UPR contribute to the pathophysiology of PCOS by disturbing the function of GCs in multiple ways (Figure 2). ER stress activates the apoptotic cascade in GCs and is associated with follicular growth arrest. It also induces

ovarian fibrosis, which is a characteristic feature of PCOS, and is mediated through greater production of profibrotic cytokines, such as TGF- β 1, by GCs. ER stress also induces the expression of AHR and activates downstream signaling in GCs, causing abnormal ovarian steroid hormone metabolism. It also perturbs COC expansion by activating Notch signaling in GCs, which might underpin the ovulatory dysfunction. The accumulation of AGEs in GCs is caused by ER stress through higher RAGE expression, which results in follicular growth arrest. In addition, ER stress in the pancreas, liver, muscle, and adipocytes induces IR and compensatory hyperinsulinemia, which worsen the HA and directly contribute to ovarian dysfunction. Thus, a vicious circle is formed by HA, hyperinsulinemia, and other proinflammatory factors, and these are connected by ER stress.

These findings indicate that ER stress represents a promising therapeutic target for PCOS. TUDCA and 4-PBA are chemical chaperones that directly reduce ER stress and have been clinically used for the treatment of liver disease and urea cycle disorders, respectively. Several natural compounds, including inositol, resveratrol, curcumin, and traditional Chinese medicines, have also been used to treat PCOS either clinically or experimentally, and it was shown that reductions in ER stress at least in part explain their effects, although the precise underlying mechanisms have not been determined (107–109). Lifestyle modification plays a role in treatment of PCOS (8), and the ER may represent a target of this, together with other local factors in the follicular microenvironment, including oxidative stress, inflammation, and the accumulation of




FIGURE 2

Functional alteration of GCs induced by ER stress in pathophysiology of PCOS. Molecules involved in the mechanism, either directly or indirectly activated by ER stress, are shown. The number in parentheses refers to the reference number of citation. ER stress is activated in the follicular microenvironment by HA and IR, two key factors underpinning the heterogenous etiology of PCOS. ER stress and the subsequent activation of the UPR contribute to the pathophysiology of PCOS by impairing the function of GCs in multiple ways. ER stress activates the apoptotic cascade in GCs and is associated with follicular growth arrest. The UPR branches, PERK-ATF4-CHOP or IRE1-TRAF2-JNK, induce several caspases-dependent apoptosis. ER stress also induces the ovarian fibrosis that is characteristic of PCOS by increasing the production of profibrotic cytokines, such as TGF-β1 and CTGF, in GCs *via* the UPR pathway, especially involved in XBP1. ER stress is also associated with high expression of AHR, AHR nuclear translocator (ARNT) and its downstream Cyp1b1 in GCs, which causes alterations in ovarian steroid hormone metabolism. In addition to this, other steroidogenic enzymes, such as Cyp19a1 and Cyp11a1, are induced by the UPR pathway. ER stress also perturbs COC expansion *via* activation of ATF4 and Notch signaling followed by the induction of ovulation-related genes, such as amphiregulin (Areg), epiregulin (Ereg), hyaluronan synthase 2 (Has2), tumor necrosis factor alpha-induced protein 6 (Tnfaip6) and cyclooxygenase 2 (COX2), in GCs, which might also contribute to the ovulatory dysfunction. ER stress is also associated with expression of HCP, resulting in a failure of follicular development. In addition, RE stress in the pancreas, liver, muscle, and adipocytes induces IR and compensatory hyperinsulinemia, which aggravate HA and directly contribute to ovarian dysfunction by impairing PI3K/Akt signaling in GCs. Thus, a vicious circle is formed by HA, hyperinsulinemia, and other proinflammatory factors, and these factors are co

AGEs. In addition, it would be interesting to evaluate the relationship between the follicular microenvironment and the gut microbiome, which is closely associated with lifestyle and plays a causative role in pathogenesis of PCOS (110, 111).

6 Conclusion

The activation of ER stress in the follicular microenvironment of patients with PCOS forms part of a vicious circle with other local factors, including high levels of androgens, oxidative stress, and inflammation, as well as with systemic features of PCOS, including IR. The abnormal follicular microenvironment causes multiple defects in GCs, contributes to the pathogenesis of PCOS, and closely interacts with the systemic features of PCOS. Further research regarding the targeting of ER stress would be useful for the development of treatments of this enigmatic syndrome that are based on its pathological mechanism.

Author contributions

HK and MH contributed to conception and design of the work and drafting of the article. AK, ZX, TT, NS, CK, JA, NT, and YU contributed to critical revision of the intellectual content of the work. YO supervised the work and contributed to critical revision of the intellectual content of the work. All authors contributed to the article and approved the submitted version.

Funding

This study was supported by the Japan Society for the Promotion of Science (JSPS) (grant numbers 21j12871 to CK, 21k16808 to YU, and 22k09614 to MH) and The Japan Society for Menopause and Women's Health (JMWH) (to YU).

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

References

1. Harada M. Pathophysiology of polycystic ovary syndrome revisited: Current understanding and perspectives regarding future research. *Reprod Med Biol* (2022) 21 (1):e12487. doi: 10.1002/rmb2.12487

2. Dumesic DA, Oberfield SE, Stener-Victorin E, Marshall JC, Laven JS, Legro RS. Scientific statement on the diagnostic criteria, epidemiology, pathophysiology, and molecular genetics of polycystic ovary syndrome. *Endocr Rev* (2015) 36(5):487-525. doi: 10.1210/er.2015-1018

3. Harada M, Takahashi N, Azhary JM, Kunitomi C, Fujii T, Osuga Y. Endoplasmic reticulum stress: A key regulator of the follicular microenvironment in the ovary. *Mol Hum Reprod* (2021) 27(1):gaaa088. doi: 10.1093/molehr/gaaa088

4. Takahashi N, Harada M, Hirota Y, Nose E, Azhary JM, Koike H, et al. Activation of endoplasmic reticulum stress in granulosa cells from patients with polycystic ovary syndrome contributes to ovarian fibrosis. *Sci Rep* (2017) 7(1):10824. doi: 10.1038/s41598-017-11252-7

5. Escobar-Morreale HF. Polycystic ovary syndrome: Definition, aetiology, diagnosis and treatment. *Nat Rev Endocrinol* (2018) 14(5):270-84. doi: 10.1038/nrendo.2018.24

6. Azziz R. Polycystic ovary syndrome. Obstetrics Gynecol (2018) 132(2):321-36. doi: 10.1097/AOG.00000000002698

7. The Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. *Fertility Sterility* (2004) 81(1):19–25. doi: 10.1016/ j.fertnstert.2003.10.004

8. Teede HJ, Misso ML, Costello MF, Dokras A, Laven J, Moran L, et al. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome†‡. *Hum Reprod* (2018) 33(9):1602–18. doi: 10.1093/humrep/dey256

9. Burt Solorzano CM, McCartney CR, Blank SK, Knudsen KL, Marshall JC. Hyperandrogenaemia in adolescent girls: Origins of abnormal gonadotropin-releasing hormone secretion. *BJOG* (2010) 117(2):143–9. doi: 10.1111/j.1471-0528.2009.02383.x

10. Azziz R, Carmina E, Chen Z, Dunaif A, Laven JS, Legro RS, et al. Polycystic ovary syndrome. *Nat Rev Dis Primers* (2016) 2:16057. doi: 10.1038/nrdp.2016.57

11. Tata B, Mimouni NEH, Barbotin AL, Malone SA, Loyens A, Pigny P, et al. Elevated prenatal anti-mullerian hormone reprograms the fetus and induces polycystic ovary syndrome in adulthood. *Nat Med* (2018) 24(6):834–46. doi: 10.1038/s41591-018-0035-5

12. Azziz R. PCOS in 2015: New insights into the genetics of polycystic ovary syndrome. *Nat Rev Endocrinol* (2016) 12(2):74–5. doi: 10.1038/nrendo.2015.230

13. Escobar-Morreale HF, Luque-Ramirez M, San Millan JL. The molecular-genetic basis of functional hyperandrogenism and the polycystic ovary syndrome. *Endocr Rev* (2005) 26(2):251–82. doi: 10.1210/er.2004-0004

14. Kaufman RJ. Stress signaling from the lumen of the endoplasmic reticulum: Coordination of gene transcriptional and translational controls. *Genes Dev* (1999) 13 (10):1211–33. doi: 10.1101/gad.13.10.1211

15. Ron D, Walter P. Signal integration in the endoplasmic reticulum unfolded protein response. *Nat Rev Mol Cell Biol* (2007) 8(7):519–29. doi: 10.1038/nrm2199

16. Walter P, Ron D. The unfolded protein response: From stress pathway to homeostatic regulation. *Science* (2011) 334(6059):1081-6. doi: 10.1126/science.1209038

17. Hetz C, Zhang K, Kaufman RJ. Mechanisms, regulation and functions of the unfolded protein response. *Nat Rev Mol Cell Biol* (2020) 21(8):421–38. doi: 10.1038/s41580-020-0250-z

18. Harding HP, Ron D. Endoplasmic reticulum stress and the development of diabetes - a review. *Diabetes* (2002) 51:S455-S61. doi: 10.2337/diabetes.51.2007.s455

19. Kaneko M, Koike H, Saito R, Kitamura Y, Okuma Y, Nomura Y. Loss of HRD1mediated protein degradation causes amyloid precursor protein accumulation and amyloid-beta generation. *J Neurosci* (2010) 30(11):3924-32. doi: 10.1523/ JNEUROSCI.2422-09.2010

20. Grootjans J, Kaser A, Kaufman RJ, Blumberg RS. The unfolded protein response in immunity and inflammation. *Nat Rev Immunol* (2016) 16(8):469-84. doi: 10.1038/nri.2016.62

21. Ren J, Bi Y, Sowers JR, Hetz C, Zhang Y. Endoplasmic reticulum stress and unfolded protein response in cardiovascular diseases. *Nat Rev Cardiol* (2021) 18(7):499–521. doi: 10.1038/s41569-021-00511-w

22. Guzel E, Arlier S, Guzeloglu-Kayisli O, Tabak MS, Ekiz T, Semerci N, et al. Endoplasmic reticulum stress and homeostasis in reproductive physiology and pathology. *Int J Mol Sci* (2017) 18(4):792-817. doi: 10.3390/ijms18040792

23. Wang C, Zhang Y. Endoplasmic reticulum stress: A new research direction for polycystic ovary syndrome? *DNA Cell Biol* (2022) 41(4):356–67. doi: 10.1089/dna.2021.1050

24. Gougeon A. Regulation of ovarian follicular development in primates: Facts and hypotheses. *Endocr Rev* (1996) 17(2):121–55. doi: 10.1210/edrv-17-2-121

25. Dumesic DA, Meldrum DR, Katz-Jaffe MG, Krisher RL, Schoolcraft WB. Oocyte environment: follicular fluid and cumulus cells are critical for oocyte health. *Fertil Steril* (2015) 103(2):303–16. doi: 10.1016/j.fertnstert.2014.11.015

26. Ajoolabady A, Lebeaupin C, Wu NN, Kaufman RJ, Ren J. ER stress and inflammation crosstalk in obesity. *Med Res Rev* (2022) 43(1):5-30. doi: 10.1002/med.21921

27. Azhary JMK, Harada M, Takahashi N, Nose E, Kunitomi C, Koike H, et al. Endoplasmic reticulum stress activated by androgen enhances apoptosis of granulosa cells *via* induction of death receptor 5 in PCOS. *Endocrinology* (2019) 160(1):119–32. doi: 10.1210/en.2018-00675

28. Eppig JJ. Oocyte control of ovarian follicular development and function in mammals. *Reproduction* (2001) 122(6):829–38. doi: 10.1530/rep.0.1220829

29. Matzuk MM, Burns KH, Viveiros MM, Eppig JJ. Intercellular communication in the mammalian ovary: Oocytes carry the conversation. *Science* (2002) 296(5576):2178–80. doi: 10.1126/science.1071965

30. Zhang Y, Yan Z, Qin Q, Nisenblat V, Chang HM, Yu Y, et al. Transcriptome landscape of human folliculogenesis reveals oocyte and granulosa cell interactions. *Mol Cell* (2018) 72(6):1021–34 e4. doi: 10.1016/j.molcel.2018.10.029

31. Alam MH, Miyano T. Interaction between growing oocytes and granulosa cells in vitro. *Reprod Med Biol* (2020) 19(1):13–23. doi: 10.1002/rmb2.12292

32. Orisaka M, Tajima K, Tsang BK, Kotsuji F. Oocyte-granulosa-theca cell interactions during preantral follicular development. *J Ovarian Res* (2009) 2(1):9. doi: 10.1186/1757-2215-2-9

33. Zhang H, Liu K. Cellular and molecular regulation of the activation of mammalian primordial follicles: Somatic cells initiate follicle activation in adulthood. *Hum Reprod Update* (2015) 21(6):779–86. doi: 10.1093/humupd/dmv037

34. Vanorny DA, Mayo KE. The role of notch signaling in the mammalian ovary. *Reproduction* (2017) 153(6):R187–204. doi: 10.1530/REP-16-0689

35. Chang HM, Qiao J, Leung PC. Oocyte-somatic cell interactions in the human ovary-novel role of bone morphogenetic proteins and growth differentiation factors. *Hum Reprod Update* (2016) 23(1):1–18. doi: 10.1093/humupd/dmw039

36. Jones ASK, Shikanov A. Follicle development as an orchestrated signaling network in a 3D organoid. J Biol Eng (2019) 13:2. doi: 10.1186/s13036-018-0134-3

37. Mikaeili S, Rashidi BH, Safa M, Najafi A, Sobhani A, Asadi E, et al. Altered FoxO3 expression and apoptosis in granulosa cells of women with polycystic ovary syndrome. *Arch Gynecol Obstetrics* (2016) 294(1):185–92. doi: 10.1007/s00404-016-4068-z

38. Lima PDA, Nivet A-L, Wang Q, Chen Y-A, Leader A, Cheung A, et al. Polycystic ovary syndrome: Possible involvement of androgen-induced, chemerin-mediated ovarian recruitment of monocytes/macrophages[†]. *Biol Reprod* (2018) 99(4):838–52. doi: 10.1093/biolre/ioy096

39. Lim JJ, Lima PDA, Salehi R, Lee DR, Tsang BK. Regulation of androgen receptor signaling by ubiquitination during folliculogenesis and its possible dysregulation in polycystic ovarian syndrome. *Sci Rep* (2017) 7(1):10272. doi: 10.1038/s41598-017-09880-0

40. Lim JJ, Han CY, Lee DR, Tsang BK. Ring finger protein 6 mediates androgeninduced granulosa cell proliferation and follicle growth *via* modulation of androgen receptor signaling. *Endocrinology* (2017) 158(4):993–1004. doi: 10.1210/en.2016-1866

41. Zhao K-K, Cui Y-G, Jiang Y-Q, Wang J, Li M, Zhang Y, et al. Effect of HSP10 on apoptosis induced by testosterone in cultured mouse ovarian granulosa cells. *Eur J Obstetrics Gynecol Reprod Biol* (2013) 171(2):301–6. doi: 10.1016/j.ejogrb.2013.09.026

42. Sun HL, Tian MM, Jiang JX, Liu CJ, Zhai QL, Wang CY, et al. Does endoplasmic reticulum stress stimulate the apoptosis of granulosa cells in polycystic ovary syndrome? *J Physiol Pharmacol* (2021) 72(5):785–792. doi: 10.26402/jpp.2021.5.13

43. Zhang Y, Weng Y, Wang D, Wang R, Wang L, Zhou J, et al. Curcumin in combination with aerobic exercise improves follicular dysfunction *via* inhibition of the hyperandrogen-induced IRE1alpha/XBP1 endoplasmic reticulum stress pathway in PCOS-like rats. *Oxid Med Cell Longev* (2021) 2021:7382900. doi: 10.1155/2021/7382900

44. Zhang Y, Wang L, Weng Y, Wang D, Wang R, Wang H, et al. Curcumin inhibits hyperandrogen-induced IRE1alpha-XBP1 pathway activation by activating the PI3K/ AKT signaling in ovarian granulosa cells of PCOS model rats. *Oxid Med Cell Longev* (2022) 2022:2113293. doi: 10.1155/2022/2113293

45. Xu Y, Pan C-S, Li Q, Zhang H-L, Yan L, Anwaier G, et al. The ameliorating effects of bushen huatan granules and kunling wan on polycystic ovary syndrome induced by dehydroepiandrosterone in rats. *Front Physiol* (2021) 12. doi: 10.3389/fphys.2021.525145

46. Pan X, Liu Y, Liu L, Pang B, Sun Z, Guan S, et al. Bushen jieyu tiaochong formula reduces apoptosis of granulosa cells via the PERK-ATF4-CHOP signaling pathway in a rat model of polycystic ovary syndrome with chronic stress. *J Ethnopharmacol* (2022) 292:114923. doi: 10.1016/j.jep.2021.114923

47. Cozzolino M, Seli E. Mitochondrial function in women with polycystic ovary syndrome. *Curr Opin Obstet Gynecol* (2020) 32(3):205-12. doi: 10.1097/GCO.000000000000619

48. Li L, Shi X, Shi Y, Wang Z. The signaling pathways involved in ovarian follicle development. *Front Physiol* (2021) 12. doi: 10.3389/fphys.2021.730196

49. Wu XK, Zhou SY, Liu JX, Pöllänen P, Sallinen K, Mäkinen M, et al. Selective ovary resistance to insulin signaling in women with polycystic ovary syndrome. *Fertility Sterility* (2003) 80(4):954–65. doi: 10.1016/S0015-0282(03)01007-0

50. Hernández-Jiménez JL, Barrera D, Espinoza-Simón E, González J, Ortíz-Hernández R, Escobar L, et al. Polycystic ovarian syndrome: Signs and feedback effects of hyperandrogenism and insulin resistance. *Gynecol Endocrinol* (2021) 38(1):2–9. doi: 10.1080/09513590.2021.2003326 51. Diamanti-Kandarakis E, Dunaif A. Insulin resistance and the polycystic ovary syndrome revisited: An update on mechanisms and implications. *Endocr Rev* (2012) 33 (6):981-1030. doi: 10.1210/er.2011-1034

52. Escobar-Morreale HF, Millán JLS. Abdominal adiposity and the polycystic ovary syndrome. *Trends Endocrinol Metab* (2007) 18(7):266–72. doi: 10.1016/j.tem.2007.07.003

53. Armanini D, Boscaro M, Bordin L, Sabbadin C. Controversies in the pathogenesis, diagnosis and treatment of PCOS: Focus on insulin resistance, inflammation, and hyperandrogenism. Int J Mol Sci (2022) 23(8):4110. doi: 10.3390/ijms23084110

54. Ding H, Zhang J, Zhang F, Zhang S, Chen X, Liang W, et al. Resistance to the insulin and elevated level of androgen: A major cause of polycystic ovary syndrome. *Front Endocrinol* (2021) 12. doi: 10.3389/fendo.2021.741764

55. Villalobos-Labra R, Subiabre M, Toledo F, Pardo F, Sobrevia L. Endoplasmic reticulum stress and development of insulin resistance in adipose, skeletal, liver, and foetoplacental tissue in diabesity. *Mol Aspects Med* (2019) 66:49–61. doi: 10.1016/j.mam.2018.11.001

56. Ozcan U, Cao Q, Yilmaz E, Lee AH, Iwakoshi NN, Ozdelen E, et al. Endoplasmic reticulum stress links obesity, insulin action, and type 2 diabetes. *Science* (2004) 306 (5695):457–61. doi: 10.1126/science.1103160

57. Ozcan U, Yilmaz E, Ozcan L, Furuhashi M, Vaillancourt E, Smith RO, et al. Chemical chaperones reduce ER stress and restore glucose homeostasis in a mouse model of type 2 diabetes. *Science* (2006) 313(5790):1137-40. doi: 10.1126/science.1128294

58. Lee SH, Park SY, Choi CS. Insulin resistance: From mechanisms to therapeutic strategies. *Diabetes Metab J* (2022) 46(1):15–37. doi: 10.4093/dmj.2021.0280

59. Zhu B, Chen Y, Xu F, Shen X, Chen X, Lv J, et al. Androgens impair beta-cell function in a mouse model of polycystic ovary syndrome by activating endoplasmic reticulum stress. *Endocr Connect* (2021) 10(3):265–72. doi: 10.1530/EC-20-0608

60. Cui Y, Ma Z, Zhao H, Chen X, Zhang Y, Guo H, et al. Activation of eIF2alpha signaling cascade is associated with testosterone-induced cell apoptosis in INS-1 cells. *Horm Metab Res* (2014) 46(8):574–80. doi: 10.1055/s-0034-1374588

61. Yuan C, Huang WQ, Guo JH, Liu XY, Yang JZ, Chen JJ, et al. Involvement of kisspeptin in androgen-induced hypothalamic endoplasmic reticulum stress and its rescuing effect in PCOS rats. *Biochim Biophys Acta Mol Basis Dis* (2021) 1867 (12):166242. doi: 10.1016/j.bbadis.2021.166242

62. Peng Y, Guo L, Gu A, Shi B, Ren Y, Cong J, et al. Electroacupuncture alleviates polycystic ovary syndrome-like symptoms through improving insulin resistance, mitochondrial dysfunction, and endoplasmic reticulum stress *via* enhancing autophagy in rats. *Mol Med* (2020) 26(1):73. doi: 10.1186/s10020-020-00198-8

63. El-Saka MH, Barhoma RA, Ibrahim RR, Elsaadany A, Alghazaly GM, Elshwaikh S, et al. Potential effect of adrenomedullin on metabolic and endocrinal dysfunctions in the experimentally induced polycystic ovary: Targeting implication of endoplasmic reticulum stress. *J Biochem Mol Toxicol* (2021) 35(5):e22725. doi: 10.1002/jbt.22725

64. Hughesdon PE. Morphology and morphogenesis of the stein-leventhal ovary and of so-called "hyperthecosis". *Obstet Gynecol Surv* (1982) 37(2):59–77. doi: 10.1097/00006254-198202000-00001

65. Meng XM, Nikolic-Paterson DJ, Lan HY. TGF-beta: The master regulator of fibrosis. Nat Rev Nephrol (2016) 12(6):325-38. doi: 10.1038/nrneph.2016.48

66. Budi EH, Schaub JR, Decaris M, Turner S, Derynck R. TGF-beta as a driver of fibrosis: physiological roles and therapeutic opportunities. *J Pathol* (2021) 254(4):358–73. doi: 10.1002/path.5680

67. Fang Y, Chang HM, Cheng JC, Klausen C, Leung PC, Yang X. Transforming growth factor-beta1 increases lysyl oxidase expression by downregulating MIR29A in human granulosa lutein cells. *Reproduction* (2016) 152(3):205–13. doi: 10.1530/REP-16-0144

68. Raja-Khan N, Urbanek M, Rodgers RJ, Legro RS. The role of TGF-beta in polycystic ovary syndrome. *Reprod Sci* (2014) 21(1):20-31. doi: 10.1177/1933719113485294

69. Cheng JC, Chang HM, Fang L, Sun YP, Leung PC. TGF-beta1 up-regulates connective tissue growth factor expression in human granulosa cells through smad and ERK1/2 signaling pathways. *PloS One* (2015) 10(5):e0126532. doi: 10.1371/journal.pone.0126532

70. Chang HM, Fang Y, Liu PP, Cheng JC, Yang X, Leung PC. Connective tissue growth factor mediates growth differentiation factor 8-induced increase of lysyl oxidase activity in human granulosa-lutein cells. *Mol Cell Endocrinol* (2016) 434:186–98. doi: 10.1016/j.mce.2016.07.007

71. Chang HM, Cheng JC, Liu Y, Klausen C, Xu C, Leung PC. Activin a-induced increase in LOX activity in human granulosa-lutein cells is mediated by CTGF. *Reproduction* (2016) 152(4):293–301. doi: 10.1530/REP-16-0254

72. Zhang X, Zhang C, Shen S, Xia Y, Yi L, Gao Q, et al. Dehydroepiandrosterone induces ovarian and uterine hyperfibrosis in female rats. *Hum Reprod* (2013) 28 (11):3074-85. doi: 10.1093/humrep/det341

73. Wang D, Wang W, Liang Q, He X, Xia Y, Shen S, et al. DHEA-induced ovarian hyperfibrosis is mediated by TGF-beta signaling pathway. *J Ovarian Res* (2018) 11(1):6. doi: 10.1186/s13048-017-0375-7

74. Lenna S, Trojanowska M. The role of endoplasmic reticulum stress and the unfolded protein response in fibrosis. *Curr Opin Rheumatol* (2012) 24(6):663-8. doi: 10.1097/BOR.0b013e3283588dbb

75. Tanjore H, Lawson WE, Blackwell TS. Endoplasmic reticulum stress as a profibrotic stimulus. *Biochim Biophys Acta* (2013) 1832(7):940-7. doi: 10.1016/ j.bbadis.2012.11.011 76. Ke B, Zhu N, Luo F, Xu Y, Fang X. Targeted inhibition of endoplasmic reticulum stress: New hope for renal fibrosis (Review). *Mol Med Rep* (2017) 16(2):1014–20. doi: 10.3892/mmr.2017.6762

77. Lerner A, Owens LA, Coates M, Simpson C, Poole G, Velupillai J, et al. Expression of genes controlling steroid metabolism and action in granulosa-lutein cells of women with polycystic ovaries. *Mol Cell Endocrinol* (2019) 486:47–54. doi: 10.1016/j.mce.2019.02.015

78. Henriquez S, Kohen P, Xu X, Villarroel C, Munoz A, Godoy A, et al. Significance of pro-angiogenic estrogen metabolites in normal follicular development and follicular growth arrest in polycystic ovary syndrome. *Hum Reprod* (2020) 35(7):1655–65. doi: 10.1093/humrep/deaa098

79. Jarrett BY, Vanden Brink H, Oldfield AL, Lujan ME. Ultrasound characterization of disordered antral follicle development in women with polycystic ovary syndrome. *J Clin Endocrinol Metab* (2020) 105(11):e3847–e61. doi: 10.1210/clinem/dgaa515

80. Yang F, Ruan YC, Yang YJ, Wang K, Liang SS, Han YB, et al. Follicular hyperandrogenism downregulates aromatase in luteinized granulosa cells in polycystic ovary syndrome women. *Reproduction* (2015) 150(4):289–96. doi: 10.1530/REP-15-0044

81. Estienne A, Mellouk N, Bongrani A, Plotton I, Langer I, Rame C, et al. Involvement of chemerin and CMKLR1 in the progesterone decrease by PCOS granulosa cells. *Reproduction* (2021) 162(6):427–36. doi: 10.1530/REP-21-0265

82. Babayev E, Lalioti MD, Favero F, Seli E. Cross-talk between FSH and endoplasmic reticulum stress: A mutually suppressive relationship. *Reprod Sci* (2016) 23(3):352–64. doi: 10.1177/1933719115602770

83. Park HJ, Park SJ, Koo DB, Lee SR, Kong IK, Ryoo JW, et al. Progesterone production is affected by unfolded protein response (UPR) signaling during the luteal phase in mice. *Life Sci* (2014) 113(1-2):60–7. doi: 10.1016/j.lfs.2014.07.033

84. Kunitomi C, Harada M, Kusamoto A, Azhary JM, Nose E, Koike H, et al. Induction of aryl hydrocarbon receptor in granulosa cells by endoplasmic reticulum stress contributes to pathology of polycystic ovary syndrome. *Mol Hum Reprod* (2021) 27(3): gaab003. doi: 10.1093/molehr/gaab003

85. Pocar P, Fischer B, Klonisch T, Hombach-Klonisch S. Molecular interactions of the aryl hydrocarbon receptor and its biological and toxicological relevance for reproduction. *Reproduction* (2005) 129(4):379–89. doi: 10.1530/rep.1.00294

86. Esser C, Lawrence B, Sherr D, Perdew G, Puga A, Barouki R, et al. Old receptor, new tricks-the ever-expanding universe of aryl hydrocarbon receptor functions. report from the 4th AHR meeting, 29–31 august 2018 in Paris, France. *Int J Mol Sci* (2018) 19 (11):3603. doi: 10.3390/ijms19113603

87. Rutkowska AZ, Diamanti-Kandarakis E. Polycystic ovary syndrome and environmental toxins. *Fertil Steril* (2016) 106(4):948-58. doi: 10.1016/j.fertnstert.2016.08.031

88. Hernandez-Ochoa I, Barnett-Ringgold KR, Dehlinger SL, Gupta RK, Leslie TC, Roby KF, et al. The ability of the aryl hydrocarbon receptor to regulate ovarian follicle growth and estradiol biosynthesis in mice depends on stage of sexual maturity. *Biol Reprod* (2010) 83(5):698–706. doi: 10.1095/biolreprod.110.087015

89. Turathum B, Gao E-M, Chian R-C. The function of cumulus cells in oocyte growth and maturation and in subsequent ovulation and fertilization. *Cells* (2021) 10(9):2292. doi: 10.3390/cells10092292

90. Richani D, Gilchrist RB. The epidermal growth factor network: Role in oocyte growth, maturation and developmental competence. *Hum Reprod Update* (2018) 24(1):1–14. doi: 10.1093/humupd/dmx029

91. Vanderhyden BC, Caron PJ, Buccione R, Eppig JJ. Developmental pattern of the secretion of cumulus expansion-enabling factor by mouse oocytes and the role of oocytes in promoting granulosa-cell differentiation. *Dev Biol* (1990) 140(2):307–17. doi: 10.1016/0012-1606(90)90081-S

92. Kopan R, Ilagan MXG. The canonical notch signaling pathway: Unfolding the activation mechanism. *Cell* (2009) 137(2):216–33. doi: 10.1016/j.cell.2009.03.045

93. Bray SJ. Notch signalling in context. Nat Rev Mol Cell Biol (2016) 17(11):722–35. doi: 10.1038/nrm.2016.94

94. Lloyd-Lewis B, Mourikis P, Fre S. Notch signalling: Sensor and instructor of the microenvironment to coordinate cell fate and organ morphogenesis. *Curr Opin Cell Biol* (2019) 61:16–23. doi: 10.1016/j.ceb.2019.06.003

95. Mašek J, Andersson ER. The developmental biology of genetic notch disorders. Development (2017) 144(10):1743–63. doi: 10.1242/dev.148007

96. Guo S, Quan S, Zou S. Roles of the notch signaling pathway in ovarian functioning. *Reprod Sci* (2021) 28(10):2770–8. doi: 10.1007/s43032-021-00610-6

97. Xie Q, Cheng Z, Chen X, Lobe CG, Liu J. The role of notch signalling in ovarian angiogenesis. J Ovarian Res (2017) 10(1):13. doi: 10.1186/s13048-017-0308-5

98. Koike H, Harada M, Kusamoto A, Kunitomi C, Xu Z, Tanaka T, et al. Notch signaling induced by endoplasmic reticulum stress regulates cumulus-oocyte complex expansion in polycystic ovary syndrome. *Biomolecules* (2022) 12(8):1037. doi: 10.3390/biom12081037

99. Jin J, Ma Y, Tong X, Yang W, Dai Y, Pan Y, et al. Metformin inhibits testosteroneinduced endoplasmic reticulum stress in ovarian granulosa cells *via* inactivation of p38 MAPK. *Hum Reprod* (2020) 35(5):1145–58. doi: 10.1093/humrep/deaa077

100. Dominiczak MH. The significance of the products of the maillard (Browning) reaction in diabetes. *Diabetic Med* (1991) 8(6):505–16. doi: 10.1111/j.1464-5491.1991.tb01643.x

101. Gill V, Kumar V, Singh K, Kumar A, Kim JJ. Advanced glycation end products (AGEs) may be a striking link between modern diet and health. *Biomolecules* (2019) 9 (12):888. doi: 10.3390/biom9120888

102. Caspar-Bell G, Dhar I, Prasad K. Role of advanced glycation end products and its receptors in the pathogenesis of cigarette smoke-induced cardiovascular disease. *Int J Angiol* (2014) 24(02):075–80. doi: 10.1055/s-0034-1396413

103. Diamanti-Kandarakis E, Piperi C, Patsouris E, Korkolopoulou P, Panidis D, Pawelczyk L, et al. Immunohistochemical localization of advanced glycation end-products (AGEs) and their receptor (RAGE) in polycystic and normal ovaries. *Histochem Cell Biol* (2007) 127(6):581–9. doi: 10.1007/s00418-006-0265-3

104. Merhi Z. Advanced glycation end products and their relevance in female reproduction. *Hum Reprod* (2014) 29(1):135-45. doi: 10.1093/humrep/det383

105. Mouanness M, Nava H, Dagher C, Merhi Z. Contribution of advanced glycation end products to PCOS key elements: A narrative review. *Nutrients* (2022) 14(17):3578. doi: 10.3390/nu14173578

106. Azhary JMK, Harada M, Kunitomi C, Kusamoto A, Takahashi N, Nose E, et al. Androgens increase accumulation of advanced glycation end products in granulosa cells by activating ER stress in PCOS. *Endocrinology* (2020) 161(2):bqaa015. doi: 10.1210/endocr/bqaa015

107. Ma R-H, Ni Z-J, Thakur K, Zhang F, Zhang Y-Y, Zhang J-G, et al. Natural compounds play therapeutic roles in various human pathologies *via* regulating endoplasmic reticulum pathway. *Med Drug Discovery* (2020) 8:100065. doi: 10.1016/j.medidd.2020.100065

108. Liu H, Yang J, Li L, Shi W, Yuan X, Wu L. The natural occurring compounds targeting endoplasmic reticulum stress. *Evid Based Complement Alternat Med* (2016) 2016:7831282. doi: 10.1155/2016/7831282

109. Michell RH. Do inositol supplements enhance phosphatidylinositol supply and thus support endoplasmic reticulum function? *Br J Nutr* (2018) 120(3):301-16. doi: 10.1017/S0007114518000946

110. Thackray VG. Sex, microbes, and polycystic ovary syndrome. *Trends Endocrinol Metab* (2019) 30(1):54–65. doi: 10.1016/j.tem.2018.11.001

111. Kusamoto A, Harada M, Azhary JMK, Kunitomi C, Nose E, Koike H, et al. Temporal relationship between alterations in the gut microbiome and the development of polycystic ovary syndrome-like phenotypes in prenatally androgenized female mice. *FASEB J* (2021) 35(11):e21971. doi: 10.1096/fj.202101051R